Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter May 13, 2019

Adverse effects of stimulant medications in children and adolescents: focus on sleep and growth disturbances

  • Donald E. Greydanus EMAIL logo , Kevin W. Cates and Nina Sadigh

References

[1] Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan. Dis Mon. 2007;53(2):65–132.10.1016/j.disamonth.2007.01.001Search in Google Scholar PubMed

[2] American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013.10.1176/appi.books.9780890425596Search in Google Scholar

[3] Kaplan G, Newcorn JH, Ivanov IS. Attention deficit hyperactivity disorder: pharmacologic management in children and adolescents. In: Greydanus DE, Calles Jr JL, Patel DR, Nazeer A, Merrick J, eds. Clinical aspects of psychopharmacology in childhood and adolescence. New York, NY: Nova Science; 2017: pp. 35–59.Search in Google Scholar

[4] Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161(9):857–64.10.1001/archpedi.161.9.857Search in Google Scholar PubMed

[5] Kessler RC, Adler L, Barkley R. The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–23.10.1176/ajp.2006.163.4.716Search in Google Scholar PubMed PubMed Central

[6] Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937;94:577–85.10.1176/ajp.94.3.577Search in Google Scholar

[7] Knobel M, Wolman M, Mason A. Hyperkinesis and organicity in children. Arch Gen Psychiatry. 1959;1(3):310–21.10.1001/archpsyc.1959.03590030094011Search in Google Scholar PubMed

[8] Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;11:CD009885.10.1002/14651858.CD009885Search in Google Scholar

[9] Greydanus DE, Kaplan G, Antshel KM. Attention deficit hyperactivity disorder: Neuropsychologic and pharmacologic aspects. In: Merrick J, ed. Child and adolescent health yearbook, 2013. New York: Nova Biomedical; 2014: p. 181–200.Search in Google Scholar

[10] Greydanus DE, Kaplan G, Patel DR. Pharmacology of autism spectrum disorder. In: Fatemi SH, ed. The molecular basis of autism. New York, NY: Springer; 2015: pp. 173–93.10.1007/978-1-4939-2190-4_9Search in Google Scholar

[11] Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev. 2016;2:CD009996.10.1002/14651858.CD009996Search in Google Scholar PubMed

[12] Doghramji K, Jangro WC. Adverse effects of psychotropic medications on sleep. Sleep Med Clin. 2016;11(4):503–14.10.1016/j.jsmc.2016.08.001Search in Google Scholar PubMed

[13] Miano S, Esposito M, Foderaro G, Ramelli GP, Pezzoli V, Manconi M. Sleep-related disorders in children with attention-deficit hyperactivity disorder: preliminary results of a full sleep assessment study. CNS Neurosci Ther. 2016;22(11):906–14.10.1111/cns.12573Search in Google Scholar PubMed PubMed Central

[14] Schneider BN, Enenbach M. Managing the risks of ADHD treatments. Curr Psychiatry Rep. 2014;16(10):479.10.1007/s11920-014-0479-3Search in Google Scholar PubMed

[15] Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med. 2010;11(7):652–8.10.1016/j.sleep.2010.02.012Search in Google Scholar PubMed

[16] Cortese S, Konofal E, Lecendreux M, Arnulf I, Mouren MC, Darra F, et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep. 2005;28(8):1007–13.10.1093/sleep/28.8.1007Search in Google Scholar PubMed

[17] Morash-Conway J, Gendron M, Corkum P. The role of sleep quality and quantity in moderating the effectiveness of medication in the treatment of children with ADHD. Atten Defic Hyperact Disord. 2017;9(1):31–8.10.1007/s12402-016-0204-7Search in Google Scholar PubMed

[18] Hiscock H, Sciberras E, Mensah F, Gerner B, Efron D, Khano S, et al. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomized controlled trial. Br Med J. 2015;350:h68.10.1136/bmj.h68Search in Google Scholar PubMed PubMed Central

[19] National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113(4):754–61.10.1542/peds.113.4.754Search in Google Scholar PubMed

[20] Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin North Am. 2008;17(2):459–74.10.1016/j.chc.2007.11.010Search in Google Scholar PubMed PubMed Central

[21] Faraone SV, Biederman J, Morley CP, Spencer TJ. Effects of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994–1009.10.1097/CHI.0b013e31817e0ea7Search in Google Scholar

[22] Harstad EB, Weaver AL, Katusic SK, Colligan RC, Kumar S, Chan E, et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics. 2014;134(4):e935–44.10.1542/peds.2014-0428Search in Google Scholar PubMed PubMed Central

[23] Kamboj MK. Disorders of the endocrine system. In: Greydanus DE, Patel DR, Omar HA, Feucht C, Merrick J, eds. Adolescent medicine: Pharmacotherapeutics in medical disorders. Berlin: De Gruyter; 2012: pp. 65–92.10.1515/9783110276367.65Search in Google Scholar

[24] Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Can Med Assoc J. 2001;165(11):1475–88.Search in Google Scholar

[25] Stein MA, Sarampote CS, Waldman ID. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003;112(5):e404.10.1542/peds.112.5.e404Search in Google Scholar PubMed

[26] Cortese M, Holtmann T, Banaschewski T. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol. 2013;54(3):227–46.10.1111/jcpp.12036Search in Google Scholar PubMed

[27] Poulton AS, Melzer E, Tait PR, Garnett SP, Cowell CT, Baur LA, et al. Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. Med J Aust. 2013;198(1):29–32.10.5694/mja12.10931Search in Google Scholar PubMed

[28] Brahmbhatt K, Hilty DM, Hah M, Han J, Angkustsiri K, Schweitzer JB. Diagnosis and treatment of attention deficit hyperactivity disorder during adolescence in the primary care setting: a concise review. J Adolesc Health. 2016;59:135–43.10.1016/j.jadohealth.2016.03.025Search in Google Scholar PubMed PubMed Central

Published Online: 2019-05-13

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.1515/ijamh-2019-0089/html
Scroll to top button